CLL Clinical Trials
Here are the 6 most popular medical studies for cll
CAR T-cell Therapy
JCAR017 + Ibrutinib + Venetoclax for Lymphoma
This trial is testing a new drug, JCAR017, to see if it is safe and effective at treating leukemia in adults. The trial will be conducted in two parts, with a separate cohort testing the drug in combination with ibrutinib or venetoclax. All subjects will be monitored for safety and efficacy, and the pharmacokinetics of JCAR017 will be studied.
Popular filter options for cll trials
CLL Clinical Trials
View 88 CLL medical studies.
Monoclonal Antibodies
Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial will assess the safety and effectiveness of a new combo drug therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Monoclonal Antibodies
Trispecific Antibody for Lymphoma
This trial is investigating a new drug, JNJ-80948543, to see if it is safe and effective. Part A is testing different doses to see what the best dose is. Part B is testing the safety of the best dose found in Part A.
Mantle Cell Lymphoma Clinical Trials
View 55 Mantle Cell Lymphoma medical studies.
Monoclonal Antibodies
Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial will assess the safety and effectiveness of a new combo drug therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Monoclonal Antibodies
Trispecific Antibody for Lymphoma
This trial is investigating a new drug, JNJ-80948543, to see if it is safe and effective. Part A is testing different doses to see what the best dose is. Part B is testing the safety of the best dose found in Part A.
Metastatic Chronic Lymphocytic Leukemia Clinical Trials
View 96 metastatic chronic lymphocytic leukemia medical studies.
Monoclonal Antibodies
Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial will assess the safety and effectiveness of a new combo drug therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Kinase Inhibitor
Ibrutinib + Fludarabine + Pembrolizumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial is testing a new combination of drugs to treat leukemia. The drugs are ibrutinib, fludarabine, and pembrolizumab. The trial is open to patients with leukemia who have not responded to other treatments.
CAR T-cell Therapy
Autologous T Cells Targeting CD19 for Chronic Lymphocytic Leukemia
This trial is testing whether using a patient's own T cells, which have been treated in the lab, can help the body build an effective immune response to kill cancer cells.
Bruton's Tyrosine Kinase (BTK) Inhibitor
PCI-32765 for Lymphocytic Leukemia
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
B-cell lymphoma-2 (BCL-2) inhibitor
Venetoclax + Ibrutinib + Obinutuzumab for Chronic Lymphocytic Leukemia
This trial is testing a new anti-cancer drug (venetoclax) to see if it can help treat patients with chronic lymphocytic leukemia who have not received previous treatment. The drug is being added to the usual treatment of ibrutinib and obinutuzumab. The trial will also investigate whether patients who receive all three treatments and have no detectable chronic lymphocytic leukemia after one year of treatment, can stop taking ibrutinib.
TP53 Positive Clinical Trials
View 9 TP53 positive medical studies.
Monoclonal Antibodies
Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial will assess the safety and effectiveness of a new combo drug therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Kinase Inhibitor
Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial is comparing two treatments for leukemia, one with ibrutinib and venetoclax, and the other with obinutuzumab and chlorambucil. The goal is to see which of these treatments results in better progression-free survival, as assessed by an independent review committee.
Kinase Inhibitor
Ibrutinib + Fludarabine + Pembrolizumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial is testing a new combination of drugs to treat leukemia. The drugs are ibrutinib, fludarabine, and pembrolizumab. The trial is open to patients with leukemia who have not responded to other treatments.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Nemtabrutinib for Chronic Lymphocytic Leukemia
This trial will compare a new drug (nemtabrutinib) to existing treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma, to see if it can prevent progression of the disease.
CD20 Positive Clinical Trials
View 8 CD20 positive medical studies.
Monoclonal Antibodies
Rituximab-based Therapy for Chronic Lymphocytic Leukemia and Richter's Syndrome
This trial is testing a new drug for people with cancer who have tried other treatments that haven't worked. The drug will be given to people in different doses to see what works best, and then given to more people to see if it is safe and effective.
Monoclonal Antibodies
Atezolizumab + BTCT4465A (Mosunetuzumab) for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
This trial is testing a new cancer drug, BTCT4465A (Mosunetuzumab), given alone or with another drug, atezolizumab. It is for people with B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia that has come back or does not respond to treatment.
Bruton's Tyrosine Kinase (BTK) Inhibitor
PCI-32765 for Lymphocytic Leukemia
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
B-cell lymphoma-2 (BCL-2) inhibitor
Venetoclax + Ibrutinib + Obinutuzumab for Chronic Lymphocytic Leukemia
This trial is testing a new anti-cancer drug (venetoclax) to see if it can help treat patients with chronic lymphocytic leukemia who have not received previous treatment. The drug is being added to the usual treatment of ibrutinib and obinutuzumab. The trial will also investigate whether patients who receive all three treatments and have no detectable chronic lymphocytic leukemia after one year of treatment, can stop taking ibrutinib.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia
This trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 3 Chronic Lymphocytic Leukemia Clinical Trials
View 96 phase 3 chronic lymphocytic leukemia medical studies.
Monoclonal Antibodies
Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial will assess the safety and effectiveness of a new combo drug therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Kinase Inhibitor
Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial is comparing two treatments for leukemia, one with ibrutinib and venetoclax, and the other with obinutuzumab and chlorambucil. The goal is to see which of these treatments results in better progression-free survival, as assessed by an independent review committee.
Monoclonal Antibodies
Pirtobrutinib for Chronic Lymphocytic Leukemia
This trial will compare the effectiveness and safety of a new drug, pirtobrutinib, to a standard drug, BR, in patients with CLL/SLL who have not been treated. Participation could last up to five years.
BTK Inhibitor
Acalabrutinib for Chronic Lymphocytic Leukemia
This trial is testing a new medication, acalabrutinib, to see if it is safe and effective in treating people with chronic lymphocytic leukemia. The trial will last for approximately 72 months and will enroll 600 participants.
BTK Inhibitor
LOXO-305 + Investigator's Choice for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial is for people with CLL or SLL who have had treatment with a BTK inhibitor. They will compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab.
Chronic Lymphocytic Leukemia Clinical Trials With No Placebo
View 96 chronic lymphocytic leukemia medical studies that do not have a placebo group.
Monoclonal Antibodies
Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial will assess the safety and effectiveness of a new combo drug therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Monoclonal Antibodies
Trispecific Antibody for Lymphoma
This trial is investigating a new drug, JNJ-80948543, to see if it is safe and effective. Part A is testing different doses to see what the best dose is. Part B is testing the safety of the best dose found in Part A.
View More Cll Trials
See another 66 many medical studies focused on cll.
Frequently Asked Questions
Introduction to cll
What are the top hospitals conducting cll research?
When it comes to advancing the treatment of Chronic Lymphocytic Leukemia (CLL), several top hospitals are at the forefront of groundbreaking clinical trials. In Houston, M D Anderson Cancer Center leads the way with 11 active CLL trials and an impressive history of 48 previous trials dedicated to this condition. This renowned center has been actively researching CLL since recording its first trial in 1998. Meanwhile, in New Yorkn Cancer Center leads the way with 11 active CLL trials and an impressive history of 48 previous trials dedicated to this condition. This renowned center has been actively researching CLL since recording its first trial in 1998. Meanwhile, in New York City, Memorial Sloan Kettering Cancer Center is making significant contributions as well. With seven ongoing CLL trials and a total of 35 completed studies so far, their dedication to finding innovative treatments began with their initial trial in 2005.
Across the country in Seattle, Fred Hutchinson Cancer Research Center is also making strides in understanding and treating CLL. Currently conducting six active clinical trials for this disease and having accumulated valuable insights from 25 prior investigations since starting their first trial back in 1995, their commitment to improving patient outcomes remains steadfast. Additionally adding itself to this roster is City of Hope Comprehensive Cancer Center located in Duarte where researchers have initiated six active cll tests while having previously conducted thirteen experiments starting from two decades ago until they started exploring new avenues only by turn on millennium clock. Meanwhile another facility known simply as City Of Hope also situated at Duarte holds involvement into five currently operational cll examinations; theirs can be traced back just recent years up till around fourteen years ago when they embarked upon investigating such cases which stood out significantly compared within them all.
These esteemed hospitals serve as beacons of hope for individuals fighting against CLL by constantly pushing boundaries through research and innovation. Their tireless efforts aim not only to extend patients' lives but also improve quality thereof; hence each advancement brings us closer towards comprehensive knowledge regarding management strategies that will ultimately lead fulfilling lives post-diagnosis
Which are the best cities for cll clinical trials?
In the realm of CLL clinical trials, several cities emerge as key players in advancing research and treatment options. Denver, Colorado leads with 43 active trials focused on Ibrutinib, Quality-of-Life Assessment, Observation, and other cutting-edge approaches. Following closely is Houston, Texas with 33 ongoing studies delving into Pirtobrutinib, Ibrutinib, JNJ-67856633, and additional avenues for exploration. New Yorker, Colorado leads with 43 active trials focused on Ibrutinib, Quality-of-Life Assessment, Observation, and other cutting-edge approaches. Following closely is Houston, Texas with 33 ongoing studies delving into Pirtobrutinib, Ibrutinib, JNJ-67856633, and additional avenues for exploration. New York City also demonstrates its prominence with 32 active trials investigating Pirtobrutinib, JNJ-80948543,JNJ-67856633 alongside other promising interventions. Anchorage in Alaska stands out with 25 active trials centered around Ibrutinib and Quality-of-Life Assessment. Finally,Duarte,Calfornia exhibits its commitment to progress through 20 ongoing trials examining innovative treatments like JCAR017 (lisocabtagene maraleucel),ibrutinib,JNJ-80948543,and others.These cities serve as beacons of hope for patients seeking participation in CLL clinical trials that foster advancements in care and ultimately improve patient outcomes
Which are the top treatments for cll being explored in clinical trials?
In the realm of CLL (chronic lymphocytic leukemia) research, several standout treatments are currently being explored in clinical trials. At the forefront is ibrutinib of CLL (chronic lymphocytic leukemia) research, several standout treatments are currently being explored in clinical trials. At the forefront is ibrutinib, a potent drug taking part in ten active trials and having amassed an impressive 87 all-time CLL trials since its debut in 2012. Close behind is acalabrutinib with eight ongoing trials and a solid foundation of 32 previous CLL studies since its introduction in 2014. Another noteworthy contender is venetoclax, participating in four active clinical trials while boasting an extensive history of 78 all-time CLL trials dating back to 2012. Lastly, pirtobrutinib shows promise with four current investigations and eight past CLR studies after first appearing on the scene in 2018. With each trial conducted, researchers strive towards advancing treatment options for individuals battling this challenging disease.
What are the most recent clinical trials for cll?
Exciting developments are underway in the field of chronic lymphocytic leukemia (CLL), with several recent clinical trials offering promising prospects for patients. A Phase 1 trial investigating a combination treatment involving tafasitamab, obinutuzumab, and acalabrutinib has shown potential in combatting CLL. Additionally, a Phase 3 trial exploring the efficacy of nemtabrutinib combined with venetoclax has yielded encouraging results. Another study known as Arm I (GEO-CM04S1) is currently in Phase 2 and holds promise for CLL patients. Furthermore, ongoing research on tafasitamab and zanubrutinib combination therapy is showing positive outcomes during its Phase 2 trial. Lastly, an investigation into acalabrutinib's effectiveness against CLL is advancing through its Phase 2 stage. These innovative trials bring hope to individuals affected by CLL and pave the way towards improved treatment options.
What cll clinical trials were recently completed?
Several clinical trials investigating potential treatments for CLL have recently been completed, showcasing the relentless efforts of researchers in advancing care for patients. Among these trials, Precision BioSciences, Inc.'s PBCAR20A trial concluded in March 2020, while Mayo Clinic's Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 study was finalized in April 2019. The University of Rochester's Shingrix vaccine trial and NHLBI's Zoster Vaccine Recombinant, Adjuvanted study were completed in February and December 2018 respectively. Additional completed trials include AbbVie-sponsored Venetoclax studies that ended in August 2018 and June 2016, M.D. Anderson Cancer Center-conducted Mycophenolate Mofetil investigations concluding in October 2017 and a June 2017 trial involving iC9/CAR-19/IL15-Transduced CB-NK Cells at the same institution. Dartmouth-Hitchcock Medical Center wrapped up their BNC105P trial in March 2018, followed by Medical College of Wisconsin's CAR-20/19-T cells investigation ending October 2017 and Virginiarix vaccine trial and NHLBI's Zoster Vaccine Recombinant, Adjuvanted study were completed in February and December 2018 respectively. Additional completed trials include AbbVie-sponsored Venetoclax studies that ended in August 2018 and June 2016, M.D. Anderson Cancer Center-conducted Mycophenolate Mofetil investigations concluding in October 2017 and a June 2017 trial involving iC9/CAR-19/IL15-Transduced CB-NK Cells at the same institution. Dartmouth-Hitchcock Medical Center wrapped up their BNC105P trial in March 2018, followed by Medical College of Wisconsin's CAR-20/19-T cells investigation ending October 2017 and Virginia Commonwealth University-conducted mycophenolate mofetil research concluding November 2015. These recent achievements fuel optimism for improved outcomes among CLL patients as we continue to advance our understanding of this complex disease.